Thermo Fisher Scientific is a global leader in providing scientific instruments, reagents, and consumables, with a focus on advancing healthcare, life sciences, and laboratory workflows. The company supports a diverse range of customers, including researchers, clinical laboratories, and pharmaceutical companies, by offering innovative solutions that enable breakthroughs in areas such as diagnostics, drug development, and environmental analysis. With a commitment to quality and efficiency, Thermo Fisher Scientific plays a crucial role in enhancing productivity and scientific discovery across various disciplines while promoting better health outcomes worldwide. Read More
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced an expansion of their strategic partnership with Sanofi to enable additional U.S. drug product manufacturing. The terms of the deal were not disclosed.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.43 per common share, payable on October 15, 2025, to shareholders of record as of September 15, 2025.
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry has tumbled by 6.3%. This performance is a stark contrast from the S&P 500’s 6.2% gain.
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.
However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2025 before the market opens on Wednesday, July 23, 2025, and will hold a conference call on the same day at 8:30 a.m. ET.
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.
Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Hitting a new 52-week low can be a pivotal moment for any stock.
These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the launch of the Thermo Scientific™ Orbitrap™ Astral™ Zoom mass spectrometer (MS) and the Thermo Scientific™ Orbitrap™ Excedion™ Pro mass spectrometer (MS) to help push the boundaries of scientific discovery. Delivering unrivaled analytical performance and speed, the instruments are designed to uncover complex biological processes that could lead to advancements in precision medicine and significant insights for complex diseases like Alzheimer’s and cancer. These Orbitrap innovations enhance Thermo Fisher’s portfolio of industry-leading solutions, delivering a connected and powerful ecosystem that enables the success of customers in proteomics, biopharmaceutical development, and scientific research.
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including Thermo Fisher (NYSE:TMO) and its peers.
